Use of kidney donors with hepatitis B, hepatitis C, or brain tumor: A single-center experience

Basit Öğe Kaydı
dc.contributor.authorTatar E.
dc.contributor.authorTuran M.N.
dc.contributor.authorFirat O.
dc.contributor.authorSezer T.O.
dc.contributor.authorSozbilen M.
dc.contributor.authorSolak I.
dc.contributor.authorToz H.
dc.contributor.authorHoscoskun C.
dc.date.accessioned2019-10-26T21:46:44Z
dc.date.available2019-10-26T21:46:44Z
dc.date.issued2012
dc.departmentEge Üniversitesien_US
dc.description.abstractIntroduction: With the rapid increase in the number of patients on the waiting lists, the idea of using organs from donors who were previously classified as "marginal" has emerged. The aim of this study was to evaluate the clinical outcomes of the patients who received kidneys from donors with hepatitis B, hepatitis C, or brain tumors. Patients and Method: Between 2003 and 2010, 27 transplantations were performed from donors with hepatitis B, hepatitis C or brain tumors between 2003 and 2010. Demographic and clinical characteristics of donors and recipients were retrospectively collected from medical files. Results: Fifteen patients received kidneys from donors with hepatitis B: 9 from deceased donors having a positive hepatitis B surface antigen (HBsAg) and six from living donors with positive HBsAg having negative results of qualitative hepatitis B DNA analysis. Two of the fifteen recipients were previously diagnosed with chronic active mild hepatitis B infection. The remaining 13, who were HBsAg (-)/anti-HBs(+) at the time of transplantation, underwent hepatitis B immune globulin and lamivudine therapy. Median follow up time was 40 ± 35 months. One patient developed decompensated liver disease owing to noncompliance to lamivudine therapy. Five patients who received grafts from anti-HCV(+) deceased donors were anti-HCV(+) at the time of transplantation with alanine aminotransferase (ALT) levels <40 U/L. All grafts remained functional at a median of 70 months. Seven subjects received grafts from deceased donors with brain tumors, none of whom had a history of a craniotomy or a ventriculoperitoneal shunt. All recipients had serious vascular access problems. No graft loss or de novo malignancies was observed among these patients after a median follow-up of 69 ± 26 months. Conclusion: With appropriate patient selection, the donated organ pool can be expanded by addition of donors with hepatitis or brain tumors. © 2012 Elsevier Inc. All rights reserved.en_US
dc.identifier.doi10.1016/j.transproceed.2012.04.028en_US
dc.identifier.endpage1603en_US
dc.identifier.issn0041-1345
dc.identifier.issue6en_US
dc.identifier.pmid22841224en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage1601en_US
dc.identifier.urihttps://doi.org/10.1016/j.transproceed.2012.04.028
dc.identifier.urihttps://hdl.handle.net/11454/18573
dc.identifier.volume44en_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.relation.ispartofTransplantation Proceedingsen_US
dc.relation.publicationcategoryKonferans Öğesi - Uluslararası - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.titleUse of kidney donors with hepatitis B, hepatitis C, or brain tumor: A single-center experienceen_US
dc.typeConference Objecten_US

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu